Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Enzyme intervenes when cancer-fighting PTEN is bound for cell's protein-destroying machinery

A protector for PTEN, a tumor-thwarting protein often missing in cancer cells, has emerged from research led by scientists at The University of Texas MD Anderson Cancer Center published online at Nature Cell Biology this week.

28 Nov 2013

Novel micro-catheter fluorescent dye method to treat aneurysm in deep brain

In March 2013, Eric Wagner told his wife to call 9-1-1 because he was feeling the worst that he had ever felt. He was rushed by EMS to University Hospitals (UH) Ahuja Medical Center, and then airlifted to UH Case Medical Center, where brain scans showed that he had a ruptured aneurysm, a leaking blister on a blood vessel that was letting blood flow into his brain and causing a stroke.

27 Nov 2013

Fluxion Biosciences reports first study results from early stage NSCLC patients

Fluxion Biosciences, Inc. announced the presentation of the first pilot study results aimed at isolating circulating tumor cells (CTCs) from early stage non-small cell lung cancer (NSCLC) patients obtained in collaboration with Dr. Max Diehn's lab at Stanford University. CTCs are cells that disseminate from primary tumors and contribute to the spread of the disease to other parts of the body.

From Fluxion Biosciences 27 Nov 2013

UMass Medical School licenses "anti-gal" technology to Agalimmune

The University of Massachusetts Medical School has licensed "anti-gal" technology developed by Professor of Surgery and Medicine Uri Galili, PhD, to newly formed biopharmaceutical company Agalimmune Ltd. for the purpose of developing innovative immunotherapies for the treatment of solid tumor cancers. Agalimmune is supported by an investment group comprising Loxbridge Research LLP and Animatrix Capital LLP and is based in London and California.

27 Nov 2013

Survivors of hematopoietic stem cell transplant benefit from expressive helping

A new study finds that survivors of hematopoietic stem cell transplant, an aggressive treatment for blood cancers, benefited from a two-part peer support process the authors call expressive helping.

27 Nov 2013

SIMM and Crown Bioscience collaborate to build MCT center in China

Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences (CAS) and Crown Bioscience, Inc., announced today that they have reached an agreement to form a strategic collaboration focused on translational oncology and to join forces to build a mouse clinical trial (MCT) center at Crown Taicang campus, Taicang, Jiangsu province, China --SIMM-Crown Mouse Clinical Trial Center, or SCMC.

26 Nov 2013

Researchers successfully target T lymphocytes which play key role in body's immune response

Researchers at the University of California, San Diego School of Medicine have successfully targeted T lymphocytes - which play a central role in the body's immune response - with another type of white blood cell engineered to synthesize and deliver bits of non-coding RNA or microRNA (miRNA).

26 Nov 2013

Researcher receives $225,000 grant to study epigenetic changes associated with chemotherapy

Western University cancer researcher Shun-Cheng (Shawn) Li, PhD, has been awarded a China-Canada Joint Health Research Initiative grant from the Canadian Institutes of Health Research (CIHR).

26 Nov 2013

Lockheed Martin donates funds to new telehealth suite dedicated for wounded warriors

Thanks to a $4 million gift from Lockheed Martin, UCLA Health System's Operation Mend now has a state-of-the-art telehealth suite, which will enable improved communication between the program's personnel, patients and partners, and a renovated recovery area for the wounded warriors who undergo surgery at the Westwood facility.

26 Nov 2013

Agalimmune established to develop innovative immunotherapeutics for treatment of cancer

Agalimmune Ltd, a biopharmaceutical company, has been created to develop innovative immunotherapeutics for the treatment of cancer, with a focus on solid tumours.

26 Nov 2013

Director of Scheie Eye Institute honored with WIO's Suzanne Veronneau Troutman Award

Joan M. O'Brien, MD, the George E. de Schweinitz and William F. Norris Professor of Ophthalmology, chair of the Department of Ophthalmology and director of the Scheie Eye Institute at the Perelman School of Medicine at the University of Pennsylvania, was recently presented with the Women in Ophthalmology's Suzanne Veronneau Troutman Award.

26 Nov 2013

Transgene welcomes SillaJen’s intention to acquire Jennerex

Transgene SA (Paris:TNG) said today that it welcomed the announcement by SillaJen, Inc. of its intention to acquire Jennerex, Inc. and has consequently given its consent to the definitive merger agreement.

26 Nov 2013

DKMS selects Remedy Informatics to provide analytics and pattern recognition technology

Remedy Informatics, Inc., the leading provider of registry-based informatics software for life sciences research and healthcare delivery, announced that DKMS, the world's largest bone marrow donor center, has selected Remedy's informatics solutions to solidify its position as an innovator and leader of hematopoietic stem cell transplantation worldwide.

26 Nov 2013

SillaJen executes definitive merger agreement to acquire Jennerex

SillaJen, Inc., a privately-held biotherapeutics and contract research company focused on the development of targeted biological products for cancer, announced today that it had executed a definitive merger agreement to acquire San Francisco-based Jennerex, Inc.

26 Nov 2013

Biocon receives regulatory approval for biosimilar product, trastuzumab

Mylan Inc. today announced that its partner Biocon has received approval for a Mylan-Biocon trastuzumab product from the Drug Controller General of India. This is the first regulatory approval for a Mylan-Biocon developed biosimilar product.

26 Nov 2013

Immune Pharmaceuticals to transfer common stock listing from NASDAQ OMX Stockholm Exchange

Immune Pharmaceuticals Inc. announced today that its common stock has been approved for trading on NASDAQ OMX First North Premier, Stockholm ("First North").

26 Nov 2013

People with cancer are at increased risk of severe complications from virus

It is often noted that very young people and the elderly are most at-risk for experiencing flu-related complications, and one expert at the University of Alabama at Birmingham says people with weakened immune systems due to diseases like cancer are also at an increased risk of severe complications from the virus.

26 Nov 2013

Arrowhead seeks approval to start ARC-520 phase 2a trial for chronic hepatitis B infection

Arrowhead Research Corporation, a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it recently filed an application for approval to begin a phase 2a clinical trial of its RNAi-based therapeutic candidate, ARC-520, for the potential treatment of chronic hepatitis B virus infection.

25 Nov 2013

CHMP adopts positive opinion for ABRAXANE with gemcitabine for treatment of metastatic pancreas

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that the European Medicines Agency's: Committee for Medicinal Products for Human Use has adopted a positive opinion for ABRAXANE (paclitaxel formulated as albumin bound nanoparticles, or nab-paclitaxel) in combination with gemcitabine for first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.

25 Nov 2013

Radiation therapy now available via latest version of ACR ppropriateness Criteria

New and updated evidence-based guidelines to help health care providers choose the most appropriate medical imaging exam or radiation therapy for a patient's clinical condition are now available via the latest version of the American College of Radiology (ACR) Appropriateness Criteria.

25 Nov 2013

Oncology News and Research

Further Reading

Enzyme intervenes when cancer-fighting PTEN is bound for cell's protein-destroying machinery

Novel micro-catheter fluorescent dye method to treat aneurysm in deep brain

Fluxion Biosciences reports first study results from early stage NSCLC patients

UMass Medical School licenses "anti-gal" technology to Agalimmune

Survivors of hematopoietic stem cell transplant benefit from expressive helping

SIMM and Crown Bioscience collaborate to build MCT center in China

Researchers successfully target T lymphocytes which play key role in body's immune response

Researcher receives $225,000 grant to study epigenetic changes associated with chemotherapy

Lockheed Martin donates funds to new telehealth suite dedicated for wounded warriors

Agalimmune established to develop innovative immunotherapeutics for treatment of cancer

Director of Scheie Eye Institute honored with WIO's Suzanne Veronneau Troutman Award

Transgene welcomes SillaJen’s intention to acquire Jennerex

DKMS selects Remedy Informatics to provide analytics and pattern recognition technology

SillaJen executes definitive merger agreement to acquire Jennerex

Biocon receives regulatory approval for biosimilar product, trastuzumab

Immune Pharmaceuticals to transfer common stock listing from NASDAQ OMX Stockholm Exchange

People with cancer are at increased risk of severe complications from virus

Arrowhead seeks approval to start ARC-520 phase 2a trial for chronic hepatitis B infection

CHMP adopts positive opinion for ABRAXANE with gemcitabine for treatment of metastatic pancreas

Radiation therapy now available via latest version of ACR ppropriateness Criteria

Industry Focus eBook - Oncology (3rd edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News